Interferon-alpha-induced changes in metallothionein expression in liver biopsies from patients with chronic hepatitis C.
An association between reactive oxygen species and liver damage has been postulated in the course of hepatitis C virus (HCV) infection. Metallothionein (MT), induced by HCV core protein and interferon (IFN), plays a role in scavenging free radicals. MT expression in liver biopsies obtained from 21 patients with chronic HCV infection before and after IFN-alpha therapy was investigated. Changes in Knodell histological activity index (HAI) scores, MT protein levels (immunohistochemistry), MT-I and MT-II messenger (m)RNA expression levels (in situ hybridization) and proliferating cell nuclear antigen (PCNA) labelling index were determined and compared in serial liver specimens. MT staining was clustered around the portal tracts with inflammatory cells and fibrosis. The pattern of MT protein before IFN-alpha therapy was similar in all patients, but was higher in IFN-sustained responders than in nonresponders after IFN-alpha therapy. HAI scores and PCNA labelling indexes were significantly reduced after IFN-alpha therapy. MT-II mRNA expression correlated positively with PCNA index before therapy and with HAI scores after therapy (P<0.05). No correlation was found between MT-I mRNA and HAI scores or PCNA index. The findings indicate that IFN-alpha-induced hepatic MT may participate in the therapeutic effects of IFN-alpha for HCV. In addition, MT-II mRNA expression may be involved in cell proliferation in the livers of patients with chronic HCV infection.
Nagamine
Takeaki
T
School of Health Science, Faculty of Medicine, Gunma University, Japan. mine@health.gunma-u.ac.jp
Suzuki
Keiji
K
Kondo
Toshihiko
T
Nakazato
Kyomi
K
Kakizaki
Satoru
S
Takagi
Hitoshi
H
Nakajima
Katuyuki
K
D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008668:Metallothionein / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha; D012333:RNA, Messenger; D008668:Metallothionein